Questions from the public: March 2023 Board meeting

# Are you going to accelerate your work on Long-term COVID-19?

The guideline on managing the long term effects of COVID-19 was first published in December 2020 and last updated in November 2021. NICE recognises this is an important area and we continue to maintain an oversight of emerging evidence. An expert group is in place to advise NICE when it would be appropriate to update the recommendations.

# Are you going to advise further on more accurate testing for Prostate health?

NICE has produced a number of guidance on this topic, which is an area of unmet need. We have published 21 pieces of guidance within the last 6 months, with 13 currently in development in addition to those products already published. All of which can be found via the following link: [Prostate cancer | Topic | NICE](https://www.nice.org.uk/guidance/conditions-and-diseases/cancer/prostate-cancer)

# What needs to be taken into account for eligibility for a pathway appraisal, other than aligning in terms of regulatory timing?

A limited number of pilots are being undertaken, with the areas selected based on the topics in the pipeline and the scope for potential efficiencies. Following the pilot the results will be evaluated and then a decision can be made on whether to broaden this to more technologies.